Holen Sie sich die Stockscreener-App
11.21
0.49%
-0.065
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt AUPH?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$11.27
Offen:
$11.3
24-Stunden-Volumen:
605.08K
Relative Volume:
0.31
Marktkapitalisierung:
$1.47B
Einnahmen:
$260.11M
Nettoeinkommen (Verlust:
$60.64M
KGV:
26.06
EPS:
0.43
Netto-Cashflow:
$92.29M
1W Leistung:
-0.93%
1M Leistung:
-11.97%
6M Leistung:
+51.35%
1J Leistung:
+58.40%
1-Tages-Spanne:
$11.13
$11.33
1-Wochen-Bereich:
$11.07
$11.87
52-Wochen-Spanne:
$6.55
$13.54
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Firmenname
Aurinia Pharmaceuticals Inc
Sektor
Branche
Telefon
250-744-2487
Adresse
#140, 14315 - 118 AVENUE, EDMONTON, BC
Vergleichen Sie AUPH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
11.21 | 1.48B | 260.11M | 60.64M | 92.29M | 0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.43 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.80 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.59 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
801.14 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
330.89 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-11-04 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-05-05 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-01-25 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-03 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-05-05 | Eingeleitet | Cowen | Outperform |
| 2020-01-10 | Eingeleitet | Jefferies | Buy |
| 2019-12-16 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-16 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-02-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-10-30 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-18 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-03-22 | Bestätigt | FBR & Co. | Outperform |
| 2016-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-17 | Bestätigt | H.C. Wainwright | Buy |
| 2016-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-05-08 | Eingeleitet | MLV & Co | Buy |
Alle ansehen
Aurinia Pharmaceuticals Inc Aktie (AUPH) Neueste Nachrichten
Can Aurinia Pharmaceuticals Inc. stock reach $100 price targetJuly 2025 Analyst Calls & Low Risk Investment Opportunities - newser.com
Can Aurinia Pharmaceuticals Inc. (IKAP) stock reach $200 price targetTrade Risk Report & Risk Adjusted Buy and Sell Alerts - newser.com
Statistical indicators supporting Aurinia Pharmaceuticals Inc.’s strengthTrade Volume Summary & Daily Chart Pattern Signals - newser.com
Technical analysis overview for Aurinia Pharmaceuticals Inc. stockTrade Ideas & Real-Time Chart Breakout Alerts - newser.com
Real time breakdown of Aurinia Pharmaceuticals Inc. stock performance2025 Top Decliners & AI Based Buy and Sell Signals - newser.com
What the charts say about Aurinia Pharmaceuticals Inc. todayRate Hike & Daily Stock Trend Reports - newser.com
Market reaction to Aurinia Pharmaceuticals Inc.’s recent newsWeekly Market Report & Risk Controlled Swing Alerts - newser.com
Predicting Aurinia Pharmaceuticals Inc. trend using moving averages2025 Geopolitical Influence & Weekly High Momentum Picks - newser.com
Aurinia Pharmaceuticals' (AUPH) "Hold (C)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Analyzing net buyer seller activity in Aurinia Pharmaceuticals Inc.2025 Fundamental Recap & Free Community Consensus Stock Picks - newser.com
Can trapped investors hope for a rebound in Aurinia Pharmaceuticals Inc.Weekly Profit Recap & Fast Moving Stock Trade Plans - newser.com
Combining machine learning predictions for Aurinia Pharmaceuticals Inc.Portfolio Return Report & Stock Portfolio Risk Management - newser.com
Will Aurinia Pharmaceuticals Inc. price bounce be sustainableMarket Risk Summary & Proven Capital Preservation Methods - newser.com
Is Shriram Asset Management Company Limited a Hybrid Growth Value Stock Worth HoldingPrice Gap Trading Strategies & Achieve Triple Digit Returns - earlytimes.in
Aurinia Pharmaceuticals Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
How Aurinia Pharmaceuticals Inc. (IKAP) stock compares with top peers2025 Short Interest & Community Consensus Picks - newser.com
Pattern recognition hints at Aurinia Pharmaceuticals Inc. upsidePortfolio Update Report & Proven Capital Preservation Methods - newser.com
Using AI based signals to follow Aurinia Pharmaceuticals Inc.July 2025 EndofMonth & Weekly Momentum Stock Picks - newser.com
Forecasting Aurinia Pharmaceuticals Inc. price range with options dataQuarterly Market Review & High Return Trade Opportunity Guides - newser.com
Could Regulatory Scrutiny Shift the Risk Profile for Aurinia Pharmaceuticals (AUPH)? - Sahm
How high can Aurinia Pharmaceuticals Inc. stock go2025 Momentum Check & High Accuracy Investment Signals - newser.com
Smart tools for monitoring Aurinia Pharmaceuticals Inc.’s price actionGap Up & Verified Stock Trade Ideas - newser.com
TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $11 - 富途牛牛
Aurinia Pharmaceuticals Hits Day Low of $11.04 Amid Price Pressure - Markets Mojo
Aurinia responds after top FDA official’s comment on lead drug - MSN
Aurinia Sinks After FDA Official Questions Its Drug in Post - MSN
FDA official’s comments spark Aurinia sell-off; Halozyme buys a biotech - BioPharma Dive
Why retail investors pile into Aurinia Pharmaceuticals Inc. stock2025 Key Lessons & Technical Pattern Based Signals - newser.com
Can swing trading help recover from Aurinia Pharmaceuticals Inc. lossesJuly 2025 Patterns & Free Fast Entry Momentum Trade Alerts - newser.com
Will earnings trigger a reversal in Aurinia Pharmaceuticals Inc.Market Trend Review & Smart Investment Allocation Insights - newser.com
What analysts say about Aurinia Pharmaceuticals Inc stockEconomic Impact on Stocks & Double Digit Profit Strategies - earlytimes.in
Aurinia Defends Benefit/Risk Profile of Lupus Nephritis Treatment After FDA Official's Retracted LinkedIn Post - MarketScreener
Aurinia Pharma rises after defending lupus drug - TradingView
Aurinia Sinks After FDA Official Questions Its Drug on LinkedIn - Bloomberg.com
Aurinia Pharma Stands By Lupus Drug After FDA Official’s Retracted Post Sparks 16% Selloff — Retail Stays Bullish On Recovery - MSN
Jefferies reiterates Hold rating on Aurinia Pharmaceuticals stock at $10 price target - Investing.com Canada
Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Gap UpStill a Buy? - MarketBeat
Aurinia Pharmaceuticals stock hits 52-week high at 13.45 USD By Investing.com - Investing.com Nigeria
Finanzdaten der Aurinia Pharmaceuticals Inc-Aktie (AUPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aurinia Pharmaceuticals Inc-Aktie (AUPH) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| TANG KEVIN | Director |
Aug 05 '25 |
Buy |
11.68 |
200,000 |
2,336,000 |
11,329,500 |
| TANG KEVIN | Director |
Aug 04 '25 |
Buy |
11.34 |
100,000 |
1,134,000 |
11,129,500 |
| Keenan Greg | Chief Medical Officer |
Aug 01 '25 |
Sale |
10.50 |
20,000 |
210,000 |
133,484 |
| Keenan Greg | Chief Medical Officer |
Mar 07 '25 |
Sale |
8.23 |
8,305 |
68,350 |
153,484 |
| Greenleaf Peter | Chief Executive Officer |
Mar 03 '25 |
Sale |
8.00 |
195,593 |
1,564,744 |
1,953,892 |
| Greenleaf Peter | Chief Executive Officer |
Mar 04 '25 |
Sale |
7.92 |
164,947 |
1,306,380 |
1,788,945 |
| Keenan Greg | Chief Medical Officer |
Mar 03 '25 |
Sale |
8.00 |
12,239 |
97,912 |
161,789 |
| Miller Joseph M | Chief Financial Officer |
Mar 03 '25 |
Sale |
8.00 |
61,859 |
494,872 |
633,515 |
| Miller Joseph M | Chief Financial Officer |
Mar 04 '25 |
Sale |
7.92 |
56,154 |
444,740 |
577,361 |
| Robertson Stephen P. | EVP, General Counsel |
Mar 03 '25 |
Sale |
8.00 |
64,872 |
518,976 |
566,883 |
1.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):